Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Hematologic Neoplasms 4Neutropenia 2Neoplasms, Plasma Cell 2Neoplasms 2Lymphoma 2Leukemia 2Infections 2Fever 2Febrile Neutropenia 2Waldenstrom Macroglobulinemia 1Urinary Tract Infections 1Staphylococcal Infections 1Spasm 1Sleep Initiation and Maintenance Disorders 1Sepsis 1Seizures 1Schizophrenia, Treatment-Resistant 1Schizophrenia 1Retinitis 1Respiratory Distress Syndrome 1Renal Insufficiency, Chronic 1Recurrence 1Pulmonary Arterial Hypertension 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pneumonia, Viral 1Pneumonia 1Pancreatic Neoplasms 1Pancreatic Diseases 1Pain 1

Interventions

ceftolozane 1Tazobactam 1Piperacillin, Tazobactam Drug Combination 1Meropenem 1Cefepime 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Other Infectious Diseases × Piperacillin, Tazobactam Drug Combination × Clear all
NCT03485950 2022-03-15

Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam

M.D. Anderson Cancer Center

Phase 2 Completed
100 enrolled 33 charts

Other Infectious Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡